PURPOSE: The p-glycoprotein (Pgp) is the most prominent member of active drug transporters leading to a multidrug-resistant phenotype. For identification of tumors functionally overexpressing Pgp in vivo, non-invasive imaging techniques are needed. PROCEDURES: Six Schiff base compounds were synthesized and labeled with (68)Ge/(68)Ga generator-derived (68)Ga. The compounds were studied in vitro in Pgp-positive tumor cells. The property of being a Pgp substrate was tested by comparison of the tracers uptake in R-3327 Dunning prostate carcinoma AT1 cells in presence and absence of the Pgp-inhibitor verapamil. In vivo investigations were performed with tumor-bearing rats imaged with micro-positron emission tomography. RESULTS: All ligands were labeled with (68)Ga in yields of >92% beside one (~55%). The tracers showed different accumulation within the cells in vitro (4-60%). In blocking experiments, the ratio (blocked to unblocked) varied from 1.8 to 1.0. For in vivo experiments, (68)Ga-ENBDMPI and (68)Ga-MFL6.MZ were selected. The tumors showed specific uptake of the tracer. Direct intratumoral injection of verapamil increased the tracer concentration by ~25% reflecting the functional Pgp activity. CONCLUSIONS: Two (68)Ga-labeled ligands appear to be valuable for imaging non-invasively the intratumoral Pgp activity. On a long term, patients with multidrug-resistant tumors pre-therapeutically may be identified prior to treatment.
PURPOSE: The p-glycoprotein (Pgp) is the most prominent member of active drug transporters leading to a multidrug-resistant phenotype. For identification of tumors functionally overexpressing Pgp in vivo, non-invasive imaging techniques are needed. PROCEDURES: Six Schiff base compounds were synthesized and labeled with (68)Ge/(68)Ga generator-derived (68)Ga. The compounds were studied in vitro in Pgp-positive tumor cells. The property of being a Pgp substrate was tested by comparison of the tracers uptake in R-3327 Dunning prostate carcinoma AT1 cells in presence and absence of the Pgp-inhibitor verapamil. In vivo investigations were performed with tumor-bearing rats imaged with micro-positron emission tomography. RESULTS: All ligands were labeled with (68)Ga in yields of >92% beside one (~55%). The tracers showed different accumulation within the cells in vitro (4-60%). In blocking experiments, the ratio (blocked to unblocked) varied from 1.8 to 1.0. For in vivo experiments, (68)Ga-ENBDMPI and (68)Ga-MFL6.MZ were selected. The tumors showed specific uptake of the tracer. Direct intratumoral injection of verapamil increased the tracer concentration by ~25% reflecting the functional Pgp activity. CONCLUSIONS: Two (68)Ga-labeled ligands appear to be valuable for imaging non-invasively the intratumoral Pgp activity. On a long term, patients with multidrug-resistant tumors pre-therapeutically may be identified prior to treatment.
Authors: Peng Hsiao; Lucy Sasongko; Jeanne M Link; David A Mankoff; Mark Muzi; Ann C Collier; Jashvant D Unadkat Journal: J Pharmacol Exp Ther Date: 2006-01-13 Impact factor: 4.030
Authors: Karen A Kurdziel; Joseph D Kalen; Jerry I Hirsch; John D Wilson; Rakesh Agarwal; Daniel Barrett; Harry D Bear; James F McCumiskey Journal: Nucl Med Biol Date: 2007-07-05 Impact factor: 2.408
Authors: Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; George A Kastis; Michael Bettan; Lars R Furenlid; Donald W Wilson; James M Woolfenden Journal: Nucl Med Biol Date: 2004-01 Impact factor: 2.408
Authors: Christoph Sauvant; Martin Nowak; Claudia Wirth; Bettina Schneider; Anne Riemann; Michael Gekle; Oliver Thews Journal: Int J Cancer Date: 2008-12-01 Impact factor: 7.396
Authors: Douglas S MacPherson; Kimberly Fung; Brendon E Cook; Lynn C Francesconi; Brian M Zeglis Journal: Dalton Trans Date: 2019-10-07 Impact factor: 4.390
Authors: Vijay Sharma; Jothilingam Sivapackiam; Scott E Harpstrite; Julie L Prior; Hannah Gu; Nigam P Rath; David Piwnica-Worms Journal: PLoS One Date: 2014-10-29 Impact factor: 3.240